Q-omics provides the consensus-scored IFNA5 profile across patient tissues and cancer cell-line models. IFNA5 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, IFNA5 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, IFNA5 RNA expression shows 6,759 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight UCEC, LUSC, and CCRCC as cancer lineages where IFNA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFNA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFNA5 survival associations across molecular data types. IFNA5 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFNA5 RNA expression–survival associations across cancer types. High IFNA5 expression shows unfavorable associations in UCEC, TGCT and READ, but favorable associations in MESO, LUSC and SCLC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for IFNA5 RNA expression.
This table summarizes IFNA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for IFNA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFNA5 shows lower tumor expression in LUSC, LUAD, KICH, KIRP and PRAD. The LUSC box plot shows higher IFNA5 RNA expression in normal versus tumor tissue (log2 FC = −0.099, t-test p < 0.001).
This table shows molecular features associated with IFNA5 in patient tissues and cancer cell lines. In patient samples, IFNA5 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IFNA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
